Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2017 Oct 11;7(10):e017178.
doi: 10.1136/bmjopen-2017-017178.

Effects of Lactobacillus rhamnosus GG and Bifidobacterium lactis Bb12 on beta-cell function in children with newly diagnosed type 1 diabetes: protocol of a randomised controlled trial

Lidia Groele  1 , Hania Szajewska  1 , Agnieszka Szypowska  1
Affiliations
Randomized Controlled Trial

Effects of Lactobacillus rhamnosus GG and Bifidobacterium lactis Bb12 on beta-cell function in children with newly diagnosed type 1 diabetes: protocol of a randomised controlled trial

Lidia Groele et al. BMJ Open. .

Abstract

Introduction: Recent evidence has demonstrated that, among other factors, dysbiosis (imbalances in the composition and function of the gut microbiota) may be relevant in the development of type 1 diabetes (T1D). Thus, gut microbiota may be a target for improving outcomes in subjects with T1D. The aim of the study is to examine the effects of Lactobacillus rhamnosus GG and Bifidobacterium lactis Bb12 on beta-cell function in children with newly diagnosed T1D.

Methods and analysis: A total of 96 children aged 8 to 17 years with newly diagnosed T1D, confirmed by clinical history and the presence of at least one positive autoantibody, will be enrolled in a double-blind, randomised, placebo-controlled trial in which they will receive L. rhamnosus GG and B. lactis Bb12 at a dose of 109 colony-forming units or an identically appearing placebo, orally, once daily, for 6 months. The follow-up will be for 12 months. The primary outcome measures will be the area under the curve of the C-peptide level during 2-hour responses to a mixed meal.

Ethics and dissemination: The Bioethics Committee approved the study protocol. The findings of this trial will be submitted to a peer-reviewed paediatric journal. Abstracts will be submitted to relevant national and international conferences.

Trial registration number: NCT03032354; Pre-results.

Keywords: RCT; children; microbiota; probiotics.

PubMed Disclaimer

Conflict of interest statement

Competing interests: None declared.

References

    1. Atkinson MA, Eisenbarth GS, Michels AW. Type 1 diabetes. Lancet 2014;383:69–82. 10.1016/S0140-6736(13)60591-7 - DOI - PMC - PubMed
    1. American Diabetes Association. Standards of medical care in diabetes-2014. Diab Care 2014:s14–s80. - PubMed
    1. Patterson CC, Dahlquist GG, Gyürüs E, et al. . Incidence trends for childhood type 1 diabetes in Europe during 1989-2003 and predicted new cases 2005-20: a multicentre prospective registration study. Lancet 2009;373:2027–33. 10.1016/S0140-6736(09)60568-7 - DOI - PubMed
    1. DIAMOND Project Group. Incidence and trends of childhood type 1 diabetes worldwide 1990-1999. Diabet Med 2006;23:857–66. 10.1111/j.1464-5491.2006.01925.x - DOI - PubMed
    1. Mejía-León ME, Petrosino JF, Ajami NJ, et al. . Fecal microbiota imbalance in Mexican children with type 1 diabetes. Sci Rep 2014;4:3814 10.1038/srep03814 - DOI - PMC - PubMed

Publication types

Associated data

LinkOut - more resources